Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Vertex Pharmaceuticals Inc / Ma (VRTX) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Vertex Pharmaceuticals Inc / Ma. Table 2 shows the detailed insider transactions. This company's CIK number is 875320.
Total stock buying since 2014: $14,032,945.
Total stock sales since 2014: $1,196,910,074.
Total stock option exercises since 2014: $345,948,365.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 15,000 | $5,843,150 | 36,186 | $17,560,365 | 0 | $0 |
| 2024 | 0 | $0 | 148,610 | $67,869,390 | 14,306 | $1,623,040 |
| 2023 | 0 | $0 | 293,658 | $101,547,730 | 106,203 | $13,301,242 |
| 2022 | 0 | $0 | 299,056 | $84,212,962 | 129,539 | $14,304,907 |
| 2021 | 25,000 | $4,926,050 | 80,192 | $17,017,085 | 3,884 | $336,043 |
| 2020 | 15,000 | $3,263,745 | 823,381 | $212,996,253 | 593,830 | $68,989,498 |
| 2019 | 0 | $0 | 749,106 | $142,436,412 | 640,272 | $64,836,003 |
| 2018 | 0 | $0 | 677,893 | $111,360,024 | 569,594 | $48,688,330 |
| 2017 | 0 | $0 | 1,829,749 | $255,631,975 | 1,303,112 | $81,084,922 |
| 2016 | 0 | $0 | 425,204 | $38,606,160 | 329,295 | $11,861,367 |
| 2015 | 0 | $0 | 1,169,000 | $146,404,893 | 1,011,116 | $40,701,778 |
| 2014 | 0 | $0 | 10,500 | $1,266,825 | 10,500 | $221,235 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 15,000 | $5,843,150 | 266 | $102,859 | 0 | $0 |
| 2025-05 | 0 | $0 | 452 | $224,427 | 0 | $0 |
| 2025-03 | 0 | $0 | 20,291 | $10,086,585 | 0 | $0 |
| 2025-02 | 0 | $0 | 15,177 | $7,146,494 | 0 | $0 |
| 2024-11 | 0 | $0 | 15,213 | $7,834,148 | 0 | $0 |
| 2024-10 | 0 | $0 | 999 | $461,198 | 0 | $0 |
| 2024-08 | 0 | $0 | 13,297 | $6,590,512 | 7,233 | $961,644 |
| 2024-07 | 0 | $0 | 17,482 | $8,669,082 | 0 | $0 |
| 2024-06 | 0 | $0 | 17,273 | $8,144,525 | 0 | $0 |
| 2024-05 | 0 | $0 | 26,147 | $11,697,035 | 7,073 | $661,396 |
| 2024-04 | 0 | $0 | 240 | $100,560 | 0 | $0 |
| 2024-02 | 0 | $0 | 54,959 | $23,157,330 | 0 | $0 |
| 2024-01 | 0 | $0 | 3,000 | $1,215,000 | 0 | $0 |
| 2023-12 | 0 | $0 | 44,190 | $17,769,377 | 25,738 | $4,552,829 |
| 2023-11 | 0 | $0 | 16,382 | $6,265,766 | 11,250 | $1,434,825 |
| 2023-10 | 0 | $0 | 31,010 | $11,309,271 | 0 | $0 |
| 2023-09 | 0 | $0 | 11,302 | $3,976,382 | 0 | $0 |
| 2023-08 | 0 | $0 | 26,086 | $9,104,522 | 10,000 | $1,275,400 |
| 2023-07 | 0 | $0 | 19,078 | $6,789,868 | 11,250 | $1,434,825 |
| 2023-06 | 0 | $0 | 8,603 | $3,002,447 | 8,603 | $1,613,320 |
| 2023-05 | 0 | $0 | 21,588 | $7,560,527 | 0 | $0 |
| 2023-04 | 0 | $0 | 32,706 | $10,717,091 | 21,300 | $1,536,582 |
| 2023-03 | 0 | $0 | 11,268 | $3,350,479 | 0 | $0 |
| 2023-02 | 0 | $0 | 41,881 | $12,355,001 | 1,304 | $244,539 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-27 | Bhatia Sangeeta N. (Director) | Sale | 266 | 386.69 | 102,859 |
| 2025-08-06 | Kewalramani Reshma (CEO & President) | Buy | 10,000 | 389.51 | 3,895,150 |
| 2025-08-06 | Sachs Bruce I (Director) | Buy | 5,000 | 389.60 | 1,948,000 |
| 2025-05-15 | Altshuler David (EVP, Chief Scientific Officer) | Sale | 52 | 424.69 | 22,083 |
| 2025-05-02 | Bhatia Sangeeta N. (Director) | Sale | 400 | 505.86 | 202,344 |
| 2025-03-13 | Altshuler David (EVP, Chief Scientific Officer) | Sale | 3,231 | 510.00 | 1,647,810 |
| 2025-03-10 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 3,242 | 499.99 | 1,620,967 |
| 2025-03-10 | Altshuler David (EVP, Chief Scientific Officer) | Sale | 3,231 | 500.00 | 1,615,500 |
| 2025-03-10 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 3,298 | 500.00 | 1,649,000 |
| 2025-03-04 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 4,058 | 485.49 | 1,970,118 |
| 2025-03-03 | Altshuler David (EVP, Chief Scientific Officer) | Sale | 3,231 | 490.00 | 1,583,190 |
| 2025-02-27 | Atkinson Edward Morrow Iii (EVP, Chief Technical Ops. Off.) | Sale | 2,650 | 475.34 | 1,259,651 |
| 2025-02-27 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 530 | 475.34 | 251,930 |
| 2025-02-27 | Altshuler David (EVP, Chief Scientific Officer) | Sale | 1,272 | 480.00 | 610,560 |
| 2025-02-25 | Atkinson Edward Morrow Iii (EVP, Chief Technical Ops. Off.) | Sale | 1,767 | 480.95 | 849,838 |
| 2025-02-25 | Ambrose Kristen (SVP & Chief Accounting Officer) | Sale | 884 | 480.95 | 425,159 |
| 2025-02-25 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 354 | 480.95 | 170,256 |
| 2025-02-25 | Altshuler David (EVP, Chief Scientific Officer) | Sale | 848 | 480.95 | 407,845 |
| 2025-02-20 | Altshuler David (EVP, Chief Scientific Officer) | Sale | 1,111 | 480.00 | 533,280 |
| 2025-02-18 | Ambrose Kristen (SVP & Chief Accounting Officer) | Sale | 671 | 455.06 | 305,345 |
| 2025-02-18 | Biller Jonathan (EVP and Chief Legal Officer) | Sale | 1,657 | 455.06 | 754,034 |
| 2025-02-11 | Atkinson Edward Morrow Iii (EVP, Chief Technical Ops. Off.) | Sale | 1,747 | 459.83 | 803,323 |
| 2025-02-11 | Ambrose Kristen (SVP & Chief Accounting Officer) | Sale | 1,376 | 459.83 | 632,726 |
| 2025-02-11 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 310 | 459.83 | 142,547 |
| 2024-11-15 | Altshuler David (EVP, Chief Scientific Officer) | Sale | 15 | 478.56 | 7,178 |
| 2024-11-08 | Kewalramani Reshma (CEO & President) | Sale | 15,198 | 515.00 | 7,826,970 |
| 2024-10-02 | Biller Jonathan (EVP and Chief Legal Officer) | Sale | 999 | 461.66 | 461,198 |
| 2024-08-30 | Bhatia Sangeeta N. (Director) | Sale | 646 | 500.00 | 323,000 |
| 2024-08-30 | Bhatia Sangeeta N. (Director) | Option Ex | 646 | 152.74 | 98,670 |
| 2024-08-30 | Leiden Jeffrey M (Executive Chairman) | Sale | 3,784 | 499.00 | 1,888,216 |
| 2024-08-08 | Bhatia Sangeeta N. (Director) | Sale | 1,292 | 466.29 | 602,446 |
| 2024-08-08 | Bhatia Sangeeta N. (Director) | Option Ex | 1,292 | 152.74 | 197,340 |
| 2024-08-07 | Bozic Carmen (EVP and CMO) | Sale | 2,280 | 476.75 | 1,086,990 |
| 2024-08-01 | Sachs Bruce I (Director) | Sale | 5,295 | 508.00 | 2,689,860 |
| 2024-08-01 | Sachs Bruce I (Director) | Option Ex | 5,295 | 125.71 | 665,634 |
| 2024-07-24 | Bozic Carmen (EVP and CMO) | Sale | 2,280 | 488.46 | 1,113,688 |
| 2024-07-22 | Kewalramani Reshma (CEO & President) | Sale | 15,202 | 497.00 | 7,555,394 |
| 2024-06-26 | Bozic Carmen (EVP and CMO) | Sale | 2,280 | 471.72 | 1,075,521 |
| 2024-06-12 | Atkinson Edward Morrow Iii (EVP, Chief Technical Ops. Off.) | Sale | 7,288 | 478.00 | 3,483,664 |
| 2024-06-12 | Bozic Carmen (EVP and CMO) | Sale | 2,280 | 478.00 | 1,089,840 |
| 2024-06-03 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 2,175 | 460.00 | 1,000,500 |
| 2024-06-03 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 3,250 | 460.00 | 1,495,000 |
| 2024-05-28 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 3,250 | 454.79 | 1,478,067 |
| 2024-05-22 | Sachs Bruce I (Director) | Sale | 7,073 | 448.00 | 3,168,704 |
| 2024-05-22 | Sachs Bruce I (Director) | Option Ex | 7,073 | 93.51 | 661,396 |
| 2024-05-20 | Kewalramani Reshma (CEO & President) | Sale | 15,202 | 447.00 | 6,795,294 |
| 2024-05-15 | Arbuckle Stuart A (EVP, COO) | Sale | 69 | 430.93 | 29,734 |
| 2024-05-15 | Altshuler David (EVP, Chief Scientific Officer) | Sale | 54 | 430.93 | 23,270 |
| 2024-05-15 | Sachdev Amit (EVP Chief Patient & Ext Af Officer) | Sale | 32 | 430.93 | 13,789 |
| 2024-05-02 | Bhatia Sangeeta N. (Director) | Sale | 467 | 402.95 | 188,177 |
| 2024-04-02 | Ambrose Kristen (SVP & Chief Accounting Officer) | Sale | 240 | 419.00 | 100,560 |
| 2024-02-26 | Atkinson Edward Morrow Iii (EVP, Chief Technical Ops. Off.) | Sale | 883 | 425.70 | 375,893 |
| 2024-02-26 | Ambrose Kristen (SVP & Chief Accounting Officer) | Sale | 883 | 425.70 | 375,893 |
| 2024-02-26 | Arbuckle Stuart A (EVP, COO) | Sale | 5,034 | 425.70 | 2,142,973 |
| 2024-02-26 | Sachdev Amit (EVP Chief Patient & Ext Af Officer) | Sale | 3,004 | 425.70 | 1,278,802 |
| 2024-02-21 | Atkinson Edward Morrow Iii (EVP, Chief Technical Ops. Off.) | Sale | 1,201 | 421.77 | 506,545 |
| 2024-02-21 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 360 | 421.77 | 151,837 |
| 2024-02-21 | Arbuckle Stuart A (EVP, COO) | Sale | 3,603 | 421.77 | 1,519,637 |
| 2024-02-21 | Altshuler David (EVP, Global Research and CSO) | Sale | 3,002 | 421.77 | 1,266,153 |
| 2024-02-21 | Sachdev Amit (EVP Chief Patient & Ext Af Officer) | Sale | 3,191 | 421.77 | 1,345,868 |
| 2024-02-20 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 480 | 420.79 | 201,979 |
| 2024-02-20 | Arbuckle Stuart A (EVP, COO) | Sale | 4,804 | 420.79 | 2,021,475 |
| 2024-02-20 | Sachdev Amit (EVP Chief Patient & Ext Af Officer) | Sale | 4,254 | 420.79 | 1,790,040 |
| 2024-02-15 | Leiden Jeffrey M (Executive Chairman) | Sale | 4,655 | 419.16 | 1,951,189 |
| 2024-02-14 | Leiden Jeffrey M (Executive Chairman) | Sale | 4,356 | 419.04 | 1,825,338 |
| 2024-02-13 | Leiden Jeffrey M (Executive Chairman) | Sale | 737 | 419.13 | 308,898 |
| 2024-02-12 | Atkinson Edward Morrow Iii (EVP, Chief Technical Ops. Off.) | Sale | 913 | 420.24 | 383,679 |
| 2024-02-12 | Ambrose Kristen (SVP & Chief Accounting Officer) | Sale | 1,374 | 420.24 | 577,409 |
| 2024-02-12 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 314 | 420.24 | 131,955 |
| 2024-02-12 | Biller Jonathan (EVP and Chief Legal Officer) | Sale | 1,738 | 418.77 | 727,822 |
| 2024-02-12 | Arbuckle Stuart A (EVP, COO) | Sale | 4,295 | 420.24 | 1,804,930 |
| 2024-02-12 | Sachdev Amit (EVP Chief Patient & Ext Af Officer) | Sale | 3,222 | 420.24 | 1,354,013 |
| 2024-02-12 | Leiden Jeffrey M (Executive Chairman) | Sale | 2,656 | 419.81 | 1,115,002 |
| 2024-01-02 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 3,000 | 405.00 | 1,215,000 |
| 2023-12-15 | Kewalramani Reshma (CEO & President) | Sale | 17,135 | 407.00 | 6,973,945 |
| 2023-12-15 | Kewalramani Reshma (CEO & President) | Option Ex | 17,135 | 171.55 | 2,939,509 |
| 2023-12-13 | Kewalramani Reshma (CEO & President) | Sale | 5,098 | 397.00 | 2,023,906 |
| 2023-12-13 | Arbuckle Stuart A (EVP, COO) | Sale | 8,603 | 399.00 | 3,432,597 |
| 2023-12-13 | Arbuckle Stuart A (EVP, COO) | Option Ex | 8,603 | 187.53 | 1,613,320 |
| 2023-12-13 | Leiden Jeffrey M (Executive Chairman) | Sale | 13,354 | 399.80 | 5,338,929 |
| 2023-11-15 | Sachdev Amit (EVP Chief Patient & Ext Af Officer) | Sale | 35 | 369.92 | 12,947 |
| 2023-11-13 | Kewalramani Reshma (CEO & President) | Sale | 5,097 | 377.00 | 1,921,569 |
| 2023-11-06 | Sachs Bruce I (Director) | Sale | 11,250 | 385.00 | 4,331,250 |
| 2023-11-06 | Sachs Bruce I (Director) | Option Ex | 11,250 | 127.54 | 1,434,825 |
| 2023-10-31 | Bozic Carmen (EVP and CMO) | Sale | 5,651 | 355.92 | 2,011,303 |
| 2023-10-17 | Bozic Carmen (EVP and CMO) | Sale | 5,651 | 373.25 | 2,109,235 |
| 2023-10-17 | Bhatia Sangeeta N. (Director) | Sale | 243 | 375.00 | 91,125 |
| 2023-10-16 | Leiden Jeffrey M (Executive Chairman) | Sale | 12,962 | 374.00 | 4,847,788 |
| 2023-10-06 | Bhatia Sangeeta N. (Director) | Sale | 242 | 360.00 | 87,120 |
| 2023-10-03 | Bozic Carmen (EVP and CMO) | Sale | 5,651 | 345.28 | 1,951,177 |
| 2023-10-02 | Biller Jonathan (EVP and Chief Legal Officer) | Sale | 610 | 346.76 | 211,523 |
| 2023-09-19 | Bozic Carmen (EVP and CMO) | Sale | 5,651 | 351.00 | 1,983,501 |
| 2023-09-05 | Bozic Carmen (EVP and CMO) | Sale | 5,651 | 352.66 | 1,992,881 |
| 2023-08-10 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 5,750 | 345.79 | 1,988,292 |
| 2023-08-10 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 10,031 | 350.00 | 3,510,850 |
| 2023-08-10 | Kearney Terrence C (Director) | Sale | 10,000 | 350.00 | 3,500,000 |
| 2023-08-10 | Kearney Terrence C (Director) | Option Ex | 10,000 | 127.54 | 1,275,400 |
| 2023-08-09 | Bhatia Sangeeta N. (Director) | Sale | 242 | 345.51 | 83,613 |
| 2023-08-09 | Altshuler David (EVP, Global Research and CSO) | Sale | 63 | 345.51 | 21,767 |
| 2023-07-17 | Kewalramani Reshma (CEO & President) | Sale | 7,828 | 355.00 | 2,778,940 |
| 2023-07-17 | Sachs Bruce I (Director) | Sale | 11,250 | 356.53 | 4,010,928 |
| 2023-07-17 | Sachs Bruce I (Director) | Option Ex | 11,250 | 127.54 | 1,434,825 |
| 2023-06-15 | Arbuckle Stuart A (EVP, COO) | Sale | 8,603 | 349.00 | 3,002,447 |
| 2023-06-15 | Arbuckle Stuart A (EVP, COO) | Option Ex | 8,603 | 187.53 | 1,613,320 |
| 2023-05-30 | Ambrose Kristen (SVP & Chief Accounting Officer) | Sale | 289 | 329.82 | 95,317 |
| 2023-05-30 | Arbuckle Stuart A (EVP, COO) | Sale | 82 | 329.82 | 27,045 |
| 2023-05-08 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 2,850 | 350.00 | 997,500 |
| 2023-05-08 | Leiden Jeffrey M (Executive Chairman) | Sale | 1,125 | 349.00 | 392,625 |
| 2023-05-05 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 422 | 350.03 | 147,712 |
| 2023-05-05 | Leiden Jeffrey M (Executive Chairman) | Sale | 879 | 349.84 | 307,509 |
| 2023-05-03 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 2,781 | 351.02 | 976,186 |
| 2023-05-03 | Leiden Jeffrey M (Executive Chairman) | Sale | 4,508 | 350.45 | 1,579,815 |
| 2023-05-02 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 1,622 | 351.74 | 570,517 |
| 2023-05-02 | Bhatia Sangeeta N. (Director) | Sale | 580 | 348.36 | 202,048 |
| 2023-05-02 | Leiden Jeffrey M (Executive Chairman) | Sale | 6,450 | 351.05 | 2,264,253 |
| 2023-04-27 | Kewalramani Reshma (CEO & President) | Sale | 3,317 | 339.44 | 1,125,912 |
| 2023-04-12 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 7,567 | 326.53 | 2,470,829 |
| 2023-04-12 | Sachs Bruce I (Director) | Sale | 21,300 | 326.53 | 6,955,088 |
| 2023-04-12 | Sachs Bruce I (Director) | Option Ex | 21,300 | 72.14 | 1,536,582 |
| 2023-04-04 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 522 | 316.59 | 165,262 |
| 2023-03-24 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 1,768 | 305.38 | 539,911 |
| 2023-03-17 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 2,000 | 297.51 | 595,016 |
| 2023-03-16 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 2,746 | 300.81 | 826,010 |
| 2023-03-13 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 2,666 | 293.54 | 782,582 |
| 2023-03-10 | Wagner Charles F Jr (EVP & Chief Financial Officer) | Sale | 2,088 | 290.69 | 606,960 |
| 2023-02-27 | Ambrose Kristen (SVP & Chief Accounting Officer) | Sale | 1,207 | 288.52 | 348,243 |
| 2023-02-27 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 354 | 288.27 | 102,048 |
| 2023-02-27 | Arbuckle Stuart A (EVP, COO) | Sale | 5,034 | 287.89 | 1,449,238 |
| 2023-02-27 | Altshuler David (EVP, Global Research and CSO) | Sale | 4,238 | 288.52 | 1,222,760 |
| 2023-02-22 | Arbuckle Stuart A (EVP, COO) | Sale | 2,401 | 294.14 | 706,220 |
| 2023-02-21 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 480 | 293.12 | 140,695 |
| 2023-02-21 | Arbuckle Stuart A (EVP, COO) | Sale | 2,402 | 293.02 | 703,846 |
| 2023-02-21 | Altshuler David (EVP, Global Research and CSO) | Sale | 4,002 | 293.13 | 1,173,118 |
| 2023-02-14 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 2,181 | 300.70 | 655,826 |
| 2023-02-14 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 320 | 298.11 | 95,393 |
| 2023-02-14 | Arbuckle Stuart A (EVP, COO) | Sale | 6,398 | 298.49 | 1,909,739 |
| 2023-02-14 | Altshuler David (EVP, Global Research and CSO) | Sale | 6,398 | 298.47 | 1,909,611 |
| 2023-02-13 | Tatsis Ourania (EVP, Chief Reg. & Quality Off.) | Sale | 275 | 298.72 | 82,148 |
| 2023-02-13 | Arbuckle Stuart A (EVP, COO) | Sale | 4,887 | 298.56 | 1,459,077 |
| 2023-02-06 | Altshuler David (EVP, Global Research and CSO) | Sale | 1,304 | 304.48 | 397,039 |
| 2023-02-06 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 1,304 | 187.53 | 244,539 |
| 2023-01-31 | Sanna Bastiano (EVP, Cell & Genetic Therapies) | Sale | 106 | 325.00 | 34,450 |
| 2023-01-31 | Sachs Bruce I (Director) | Sale | 1,200 | 325.01 | 390,012 |
| 2023-01-31 | Sachs Bruce I (Director) | Option Ex | 1,200 | 72.14 | 86,568 |
| 2023-01-30 | Carney Lloyd (Director) | Sale | 2,700 | 320.87 | 866,357 |
| 2023-01-27 | Lee Yuchun (Director) | Sale | 1,429 | 322.28 | 460,538 |
| 2023-01-27 | Lee Yuchun (Director) | Option Ex | 1,429 | 72.14 | 103,088 |
| 2023-01-26 | Lee Yuchun (Director) | Sale | 4,000 | 318.44 | 1,273,752 |
| 2023-01-26 | Lee Yuchun (Director) | Option Ex | 4,000 | 72.14 | 288,560 |
| 2023-01-25 | Kewalramani Reshma (CEO & President) | Sale | 10,000 | 315.05 | 3,150,500 |
Insider trading activities including stock purchases, stock sales, and option exercises of VRTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Vertex Pharmaceuticals Inc / Ma (symbol VRTX, CIK number 875320) see the Securities and Exchange Commission (SEC) website.